Key result
In patients with systolic heart failure, torsemide significantly reduced total heart failure readmissions compared to furosemide (RR 0.41; 95% CI 0.28-0.61; p<0.0001).
Why the study?
Does torsemide reduce heart failure and cardiovascular readmissions in patients with systolic heart failure compared to furosemide?
Population
2 randomized controlled trials pooling 471 patients with systolic heart failure
Comparison
Torsemide vs Furosemide
Design
Meta-analysis
Authors
Loading...
Supports torsemide preference over furosemide to reduce HF readmissions in systolic HF; confirms benefit in Level 1 meta-analysis.
Meta-Analysis (n=471)
Does torsemide reduce heart failure and cardiovascular readmissions in patients with systolic heart failure compared to furosemide?
Relative Risk: 0.41 (95% CI 0.28–0.61)
p-value: p=< 0.0001
In patients with systolic heart failure, torsemide significantly reduces heart failure and cardiovascular-related hospital readmissions compared with furosemide.
James J. DiNicolantonio (2012) conducted a meta-analysis in Systolic heart failure (n=471). Torsemide vs. Furosemide was evaluated on Total HF readmissions (RR 0.41, 95% CI 0.28-0.61, p=< 0.0001). In patients with systolic heart failure, torsemide significantly reduced total heart failure readmissions compared to furosemide (RR 0.41; 95% CI 0.28-0.61; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: